Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.59 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.59 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24254584 | 0.90 | MEN1 (0.64) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL24254505 | 0.87 | LMNA (0.79) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL24254506 | 0.85 | KMT2A (0.70) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL8269613 | 0.81 | KMT2A (0.65) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL26188045 | 0.79 | ALDH1A1 (0.57) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL3222675 | 0.79 | MEN1 (0.51) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL24254549 | 0.79 | SMN1; SMN2 (0.67) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL25242669 | 0.78 | ALDH1A1 (0.61) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL24254547 | 0.76 | MEN1 (0.58) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL25283909 | 0.76 | CA1 (0.54) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2022035804-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP1 | MEN1 3058/4885KMT2A 326/4885MAPT 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.